Retension Pharmaceuticals closes $15 million Series B financing to advance RTN-001 for uncontrolled hypertension. The funding supports Phase 2b trials and a new patent issuance.
Amount Raised
$15 Million
Round Type
Series B
McleanBiotechnologyHealthcareHealth CareTherapeuticsPharmaceuticalBiopharmaDescription
Retension Pharmaceuticals, focused on hypertension therapies, successfully closed its $15 million Series B financing. This funding will aid in advancing the clinical development of RTN-001 for patients with uncontrolled and resistant hypertension. Alongside this, a US patent for RTN-001 has been issued, extending protection through at least 2044. Dr
Quick answer
Retension Pharmaceuticals raised $15 Million in a Series B round, dated August 6, 2025. Retension Pharmaceuticals is based in Mclean, Virginia, United States.
- How much did Retension Pharmaceuticals raise?
- Retension Pharmaceuticals raised $15 Million in a Series B round on August 6, 2025.
- What does Retension Pharmaceuticals do?
- Retension Pharmaceuticals is developing RTN-001, a differentiated, tissue-targeted PDE5 inhibitor that has been optimized for the treatment of uncontrolled hypertension.
- Where is Retension Pharmaceuticals based and how big is it?
- Retension Pharmaceuticals is based in Mclean, Virginia, United States. Fundz records about 10 employees.
- Who are the decision-makers at Retension Pharmaceuticals?
- Fundz holds 1 contact at Retension Pharmaceuticals. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Healthcare and Therapeutics around the same time
Companies in the same sectors as Retension Pharmaceuticals that raised within 45 days of this round, from Fundz verified event records.
- Os Therapies raised $3.8M on September 2, 2025.
- Os Therapies raised $4.2M on June 23, 2025.
- TNF Pharmaceuticals raised $7M on September 2, 2025.
- Pelthos Therapeutics raised $50M on July 1, 2025.
- Biofrontera raised $11M on June 27, 2025.
- Talphera, Inc. raised $17M on September 10, 2025.
Who to call at Retension Pharmaceuticals, and when
A new round usually means Retension Pharmaceuticals is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Retension Pharmaceuticals raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Retension Pharmaceuticals, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Retension Pharmaceuticals. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Retension Pharmaceuticals raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansRetension Pharmaceuticals raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.